Skip to main content
Erschienen in: Tumor Biology 12/2014

01.12.2014 | Research Article

Association between endothelial nitric oxide synthase 894G>T polymorphism and prostate cancer risk: a meta-analysis of literature studies

verfasst von: Cheng Zhao, Weiqian Yan, Xiongbing Zu, Minfeng Chen, Longfei Liu, Shushan Zhao, Hong Liu, Xia Hu, Renna Luo, Yang Xia, Lin Qi

Erschienen in: Tumor Biology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

To date, several studies have been conducted to assess the association between endothelial nitric oxide synthase (eNOS) gene 894G > T polymorphism and prostate cancer (PCa) risk, but the results are conflicting. To derive a more precise estimation of the relationship between 894G > T polymorphism and PCa risk, the present meta-analysis was performed. A total of eight case–control studies were included in this meta-analysis. The pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated to evaluate the associations. Our results suggested that 894G > T polymorphism is associated with PCa risk under codominant (GT vs. GG) (OR = 1.11, 95 % CI = 1.01–1.22, P = 0.04) and overdominant (GT vs. GG + TT) (OR = 1.12, 95 % CI = 1.02–1.23, P = 0.02) models in the overall population, while there are no associations observed under dominant (GT + TT vs. GG), recessive (TT vs. GG + GT), and allelic (T vs. G) models. Moreover, when the eligible studies were stratified according to sources of control, significant association between 894G > T polymorphism and susceptibility of PCa was also identified under codominant (OR = 1.12, 95 % CI = 1.01–1.24, P = 0.03) and overdominant (OR = 1.13, 95 % CI = 1.02–1.25, P = 0.02) models when using healthy individuals as control. However, there are no significant associations found under any genetic models when using BPH patients as control group. In conclusion, the present meta-analysis suggested that the eNOS gene 894G > T polymorphism might be a risk factor in the onset of PCa.
Literatur
1.
2.
3.
Zurück zum Zitat Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470:214–20.CrossRef Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470:214–20.CrossRef
4.
Zurück zum Zitat Hao Y, Montiel R, Huang Y. Endothelial nitric oxide synthase (eNOS) 894G > T polymorphism is associated with breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;124:809–13.CrossRef Hao Y, Montiel R, Huang Y. Endothelial nitric oxide synthase (eNOS) 894G > T polymorphism is associated with breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;124:809–13.CrossRef
6.
Zurück zum Zitat Chen J, Yuan T, Liu M, Chen P. Association between TCF7L2 gene polymorphism and cancer risk: a meta-analysis. PLoS One. 2013;8:e71730.CrossRef Chen J, Yuan T, Liu M, Chen P. Association between TCF7L2 gene polymorphism and cancer risk: a meta-analysis. PLoS One. 2013;8:e71730.CrossRef
7.
Zurück zum Zitat Amankwah EK, Sellers TA, Park JY. Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis. 2012;33:1259–69.CrossRef Amankwah EK, Sellers TA, Park JY. Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis. 2012;33:1259–69.CrossRef
8.
Zurück zum Zitat Bhowmick R, Girotti AW. Pro-survival and pro growth effects of stress-induced nitric oxide in a prostate cancer photodynamic therapy model. Cancer Lett. 2013. doi:10.1016/j10.1016/j. Bhowmick R, Girotti AW. Pro-survival and pro growth effects of stress-induced nitric oxide in a prostate cancer photodynamic therapy model. Cancer Lett. 2013. doi:10.1016/j10.1016/j.
9.
Zurück zum Zitat Dillioglugil MO, Mekik H, Muezzinoglu B, Ozkan TA, Demir CG, et al. Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer. Int Urol Nephrol. 2012;44:1691–6.CrossRef Dillioglugil MO, Mekik H, Muezzinoglu B, Ozkan TA, Demir CG, et al. Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer. Int Urol Nephrol. 2012;44:1691–6.CrossRef
10.
Zurück zum Zitat Singh S, Gupta AK. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol. 2011;67:1211–24.CrossRef Singh S, Gupta AK. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol. 2011;67:1211–24.CrossRef
11.
Zurück zum Zitat Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis. 2013;34:503–12.CrossRef Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis. 2013;34:503–12.CrossRef
12.
Zurück zum Zitat Le X, Wei D, Huang S, Lancaster Jr JR, Xie K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci U S A. 2005;102:8758–63.CrossRef Le X, Wei D, Huang S, Lancaster Jr JR, Xie K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci U S A. 2005;102:8758–63.CrossRef
13.
Zurück zum Zitat Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, et al. Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer. J Gene Med. 2010;12:755–65.CrossRef Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, et al. Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer. J Gene Med. 2010;12:755–65.CrossRef
14.
Zurück zum Zitat Xie K, Huang S, Dong Z, Juang SH, Gutman M, et al. Transfection with the iNOS gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med. 1995;181:1333–43.CrossRef Xie K, Huang S, Dong Z, Juang SH, Gutman M, et al. Transfection with the iNOS gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med. 1995;181:1333–43.CrossRef
15.
Zurück zum Zitat Heller A. Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers. ChemMedChem. 2008;3:1493–9.CrossRef Heller A. Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers. ChemMedChem. 2008;3:1493–9.CrossRef
16.
Zurück zum Zitat Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev. 2007;27:317–52.CrossRef Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev. 2007;27:317–52.CrossRef
17.
Zurück zum Zitat Tong X, Li H. eNOS protects prostate cancer cells from TRAIL-induced apoptosis. Cancer Lett. 2004;210:63–71.CrossRef Tong X, Li H. eNOS protects prostate cancer cells from TRAIL-induced apoptosis. Cancer Lett. 2004;210:63–71.CrossRef
18.
Zurück zum Zitat Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008;452:646–9.CrossRef Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008;452:646–9.CrossRef
19.
Zurück zum Zitat Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A. 2000;97:2832–5.CrossRef Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A. 2000;97:2832–5.CrossRef
20.
Zurück zum Zitat Veldmana BA, Spieringb W, Doevendansc PA, Vervoorta G, Kroonb AA, et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens. 2002;20:2023–7.CrossRef Veldmana BA, Spieringb W, Doevendansc PA, Vervoorta G, Kroonb AA, et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens. 2002;20:2023–7.CrossRef
21.
Zurück zum Zitat Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev. 2002;11:343–50.CrossRef Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev. 2002;11:343–50.CrossRef
22.
Zurück zum Zitat Brankovic A, Brajuskovic G, Nikolic Z, Vukotic V, Cerovic S, et al. Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population. Int J Exp Pathol. 2013;94:355–61.CrossRef Brankovic A, Brajuskovic G, Nikolic Z, Vukotic V, Cerovic S, et al. Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population. Int J Exp Pathol. 2013;94:355–61.CrossRef
23.
Zurück zum Zitat Marangoni K, Neves AF, Cardoso AM, Santos WK, Faria PC, et al. The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prev. 2006;30:7–13.CrossRef Marangoni K, Neves AF, Cardoso AM, Santos WK, Faria PC, et al. The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prev. 2006;30:7–13.CrossRef
24.
Zurück zum Zitat Lee KM, Kang D, Park SK, Berndt SI, Reding D, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis. 2009;30:621–5.CrossRef Lee KM, Kang D, Park SK, Berndt SI, Reding D, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis. 2009;30:621–5.CrossRef
25.
Zurück zum Zitat Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomark Prev. 2008;17:972–7.CrossRef Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomark Prev. 2008;17:972–7.CrossRef
26.
Zurück zum Zitat Chen ZG, Zhou W, Tao ZH, Chen W. Association of endothelial nitric oxide synthase gene polymorphism with prostate cancer. Zhong Guo Nan Ke Xue Za Zhi. 2011;25(7):18–21. Chen ZG, Zhou W, Tao ZH, Chen W. Association of endothelial nitric oxide synthase gene polymorphism with prostate cancer. Zhong Guo Nan Ke Xue Za Zhi. 2011;25(7):18–21.
27.
Zurück zum Zitat Ziaei SAM, Samzadeh M, Jamaldini SH, Afshari M, Haghdoost AA, et al. Endothelial nitric oxide synthase Glu298Asp polymorphism as a risk factor for prostate cancer. Int J Biol Markers. 2012;00:1–6. Ziaei SAM, Samzadeh M, Jamaldini SH, Afshari M, Haghdoost AA, et al. Endothelial nitric oxide synthase Glu298Asp polymorphism as a risk factor for prostate cancer. Int J Biol Markers. 2012;00:1–6.
28.
Zurück zum Zitat Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol Oncol. 2013;31:1132–40.CrossRef Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol Oncol. 2013;31:1132–40.CrossRef
29.
Zurück zum Zitat DerSimonian R, Laird N. Meta analysis in clinical trials. Control Clin Trials. 1996;7:177–88.CrossRef DerSimonian R, Laird N. Meta analysis in clinical trials. Control Clin Trials. 1996;7:177–88.CrossRef
30.
Zurück zum Zitat DerSimonian R. Combining evidence from clinical trials. Anesth Analg. 1990;70:475–6.CrossRef DerSimonian R. Combining evidence from clinical trials. Anesth Analg. 1990;70:475–6.CrossRef
31.
Zurück zum Zitat Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.CrossRef Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.CrossRef
32.
Zurück zum Zitat Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: a review. World J Surg Oncol. 2013;11:118.CrossRef Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: a review. World J Surg Oncol. 2013;11:118.CrossRef
33.
Zurück zum Zitat Ruisanchez E, Dancs P, Kerek M, Nemeth T, Farago B, et al. Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. FASEB J. 2013;28:880–90.CrossRef Ruisanchez E, Dancs P, Kerek M, Nemeth T, Farago B, et al. Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. FASEB J. 2013;28:880–90.CrossRef
34.
Zurück zum Zitat Deqiu Z, Kang L, Jiali Y, Baolin L, Gaolin L. Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium. Biochimie. 2011;93:506–12.CrossRef Deqiu Z, Kang L, Jiali Y, Baolin L, Gaolin L. Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium. Biochimie. 2011;93:506–12.CrossRef
35.
Zurück zum Zitat Feletou M, Lonchampt M, Coge F, Galizzi J-P, Bassoullet C, et al. Regulation of murine airway responsiveness by eNOS. Am J Physiol Lung Cell Mol Physiol. 2001;281:258–67.CrossRef Feletou M, Lonchampt M, Coge F, Galizzi J-P, Bassoullet C, et al. Regulation of murine airway responsiveness by eNOS. Am J Physiol Lung Cell Mol Physiol. 2001;281:258–67.CrossRef
36.
Zurück zum Zitat Song Y, Zhao XP, Song K, Shang ZJ. Ephrin-A1 Is Up-regulated by hypoxia in cancer cells and promotes angiogenesis of HUVECs through a coordinated cross-talk with eNOS. PLoS One. 2013;8:e74464.CrossRef Song Y, Zhao XP, Song K, Shang ZJ. Ephrin-A1 Is Up-regulated by hypoxia in cancer cells and promotes angiogenesis of HUVECs through a coordinated cross-talk with eNOS. PLoS One. 2013;8:e74464.CrossRef
37.
Zurück zum Zitat Funke S, Risch A, Nieters A, Hoffmeister M, Stegmaier C, et al. Genetic polymorphisms in genes related to oxidative stress (GSTP1, GSTM1, GSTT1, CAT, MnSOD, MPO, eNOS) and survival of rectal cancer patients after radiotherapy. J Cancer Epidemiol. 2009;2009:302047.CrossRef Funke S, Risch A, Nieters A, Hoffmeister M, Stegmaier C, et al. Genetic polymorphisms in genes related to oxidative stress (GSTP1, GSTM1, GSTT1, CAT, MnSOD, MPO, eNOS) and survival of rectal cancer patients after radiotherapy. J Cancer Epidemiol. 2009;2009:302047.CrossRef
38.
Zurück zum Zitat Jang MJ, Jeon YJ, Kim JW, Chong SY, Hong SP, et al. Association of eNOS polymorphisms (-786 T > C, 4a4b, 894G > T) with colorectal cancer susceptibility in the Korean population. Gene. 2013;512:275–81.CrossRef Jang MJ, Jeon YJ, Kim JW, Chong SY, Hong SP, et al. Association of eNOS polymorphisms (-786 T > C, 4a4b, 894G > T) with colorectal cancer susceptibility in the Korean population. Gene. 2013;512:275–81.CrossRef
39.
Zurück zum Zitat Wu JH, Yang K, Ma HS, Xu Y. Association of endothelia nitric oxide synthase gene rs1799983 polymorphism with susceptibility to prostate cancer: a meta-analysis. Tumour Biol. 2014. Wu JH, Yang K, Ma HS, Xu Y. Association of endothelia nitric oxide synthase gene rs1799983 polymorphism with susceptibility to prostate cancer: a meta-analysis. Tumour Biol. 2014.
Metadaten
Titel
Association between endothelial nitric oxide synthase 894G>T polymorphism and prostate cancer risk: a meta-analysis of literature studies
verfasst von
Cheng Zhao
Weiqian Yan
Xiongbing Zu
Minfeng Chen
Longfei Liu
Shushan Zhao
Hong Liu
Xia Hu
Renna Luo
Yang Xia
Lin Qi
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2097-4

Weitere Artikel der Ausgabe 12/2014

Tumor Biology 12/2014 Zur Ausgabe

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.